# RemSleep Holdings Inc.: Form 10-Q for the period ended Jun 30, 2026 - Company: [RemSleep Holdings Inc.](/companies/rmsl.md) (CIK 1412126) - Form: 10-Q - Filed: 2026-08-14 - Accepted by EDGAR: Aug 14, 2026, 11:07 ET - Period: 2026-06-30 - Accession: 0001683168-26-006414 - Inline XBRL: yes - Main document: https://www.sec.gov/Archives/edgar/data/1412126/000168316826006414/remsleep_i10q-063026.htm - All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1412126/000168316826006414/ ## Figures reported in this filing Standardized XBRL line items for the period ended 2026-06-30. | Line item | Period | Value | XBRL concept | | --- | --- | ---: | --- | | Revenue | 6 months, 2026-01-01 to 2026-06-30 | $0 | us-gaap:Revenues | | Cost of revenue | 6 months, 2026-01-01 to 2026-06-30 | $0 | us-gaap:CostOfRevenue | | Gross profit | 6 months, 2026-01-01 to 2026-06-30 | $0 | us-gaap:GrossProfit | | Research and development | 6 months, 2026-01-01 to 2026-06-30 | $0 | us-gaap:ResearchAndDevelopmentExpense | | Operating income | 6 months, 2026-01-01 to 2026-06-30 | −$267.6k | us-gaap:OperatingIncomeLoss | | Interest expense | 6 months, 2026-01-01 to 2026-06-30 | $84.0k | us-gaap:InterestExpenseNonoperating | | Income tax | 6 months, 2026-01-01 to 2026-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit | | Net income | 6 months, 2026-01-01 to 2026-06-30 | −$393.4k | us-gaap:NetIncomeLoss | | Operating cash flow | 6 months, 2026-01-01 to 2026-06-30 | −$418.4k | us-gaap:NetCashProvidedByUsedInOperatingActivities | | Capital expenditure | 6 months, 2026-01-01 to 2026-06-30 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | | Current assets | at 2026-06-30 | $79.3k | us-gaap:AssetsCurrent | | Total assets | at 2026-06-30 | $153.9k | us-gaap:Assets | | Current liabilities | at 2026-06-30 | $397.4k | us-gaap:LiabilitiesCurrent | | Total liabilities | at 2026-06-30 | $434.8k | us-gaap:Liabilities | | Shareholders' equity | at 2026-06-30 | −$280.9k | us-gaap:StockholdersEquity | | Shares outstanding | at 2026-06-30 | 1,739,610,123 shares | dei:EntityCommonStockSharesOutstanding | ## Management's discussion and analysis As filed, 9,744 characters. ### Forward-looking Statements Except for statements of historical fact, the information presented herein constitutes forward-looking statements. These forward-looking statements generally can be identified by phrases such as “anticipates,” “believes,” “estimates,” “expects,” “forecasts,” “foresees,” “intends,” “plans,” or other words of similar import. Similarly, statements herein that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, our ability to: successfully commercialize our technology; generate revenues and achieve profitability in an intensely competitive industry; compete in products and prices with substantially larger and better capitalized competitors; secure, maintain and enforce a strong intellectual property portfolio; attract additional capital sufficient to finance our working capital requirements, as well as any investment of plant, property and equipment; develop a sales and marketing infrastructure; identify and maintain relationships with third party suppliers who can provide us a reliable source of raw materials; acquire, develop, or identify for our own use, a manufacturing capability; attract and retain talented individuals; continue operations during periods of uncertain general economic or market conditions, and; other events, factors and risks previously and from time to time disclosed in our filings with the Securities and Exchange Commission. Although we believe the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. You should not place undue reliance on our forward-looking statements, which speak only as of the date of this report. Except as required by law, we do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. ### Overview We were incorporated in the State of Nevada on June 6, 2007. On August 2, 2010, we changed our name from Bella Viaggio, Inc. to Kat Gold Holdings Corp. Effective January 1, 2015, we completed an exchange agreement to purchase 100% of the outstanding interests of REMSleep LLC in exchange for 50,000,000 common shares of REMSleep Holdings, Inc.’s stock, at which time REMSleep LLC became our wholly-owned subsidiary and adopted their business of developing and distributing our sleep apnea products. On January 5, 2015, we changed our name to REMSleep Holdings, Inc. to reflect our new business model. Our officers have 35 years of sleep-industry experience, including having been employed at sleep industry companies. Our officers invented our DeltaWave CPAP interface (the “DeltaWave”) as an innovative new device to treat patients with sleep apnea. The patent-pending DeltaWave product is a nasal-pillows type interface that will result in better comfort and, therefore, better compliance since it was specifically designed with unique airflow characteristics to enable patients with sleep apnea to breathe normally. A survey that appeared in DME Business found that 89% of patients stated that mask-interface comfort was their primary concern. The primary issue that we have addressed with the DeltaWave is the “work of breathing” component. We believe that our DeltaWave is designed to effectively address the stubborn issues that continue to affect a patient’s ability to comply with treatment, as follows: - Does not disrupt normal breathing mechanics; - Is not claustrophobic; - Causes zero work of breathing (WOB); - Minimizes or eliminates drying of the sinuses; - Uses less driving pressure; and - Allows users to feel safe and secure while sleeping. On June 28, 2016, we applied for a patent for a new, innovative sleep apnea product that serves as an interface for the delivery of CPAP therapy and other respiratory needs. Our goal is to develop sleep products that achieve optimum compliance and comfort for CPAP patients. On April 27, 2021, Remsleep was awarded utility patent 10987481 for its new Deltawave CPAP Pillows Mask for delivery of CPAP therapy and other respiratory needs. On March 5, 2024, Remsleep was awarded design patent D1,017,025 S. Our goal is to continue to develop sleep products for the treatment of OSA and capture 10% of the market in the next 24 months. Our website is located at: https://remsleep.com. ### Results of Operations ### The six months ended June 30, 2026 compared to the six months ended June 30, 2025 #### Revenues We had no revenue for the six months ended June 30, 2026 and 2025. #### Operating Expenses Professional fees were $8,580 and $7,800 for the six months ended June 30, 2026 and 2025, respectively, an increase of $780 or 10.0%. Professional fees consist mostly of accounting, audit and legal fees. Compensation expense was $29,700 and $27,000 for the six months ended June 30, 2026 and 2025, respectively, an increase of $2,700 or 10.0%. Compensation was paid to our former CEO and to Ms. Michaels and Mr. Marshall. Development expenses were $0 and $17,200 for the six months ended June 30, 2026 and 2025, respectively, a decrease of $17,200. Our development expenses have decreased in the current period as we have completed the development and testing of our DeltaWave product. Lease expenses were $6,200 and $24,891 for the six months ended June 30, 2026 and 2025, respectively, a decrease of $18,691 or 75.1%. In the current period we have a new, less expensive lease, in a new location. General and administrative expenses (“G&A”) were $223,138 and $54,424 for the six months ended June 30, 2026 and 2025, respectively, an increase of $168,714 or 310.0%. Our largest G&A expenses in the current period consist principally of product expense and selling expense for payments to outside salespeople. #### Other Expenses The total other expense of $125,792 for the six months ended June 30, 2026, included $83,965 for interest expense and a loss on issuance of convertible debt of $94,454. These losses were partially offset by a $36,136 gain on conversion of debt and a $16,491 gain on the change in fair value of derivatives. The total other income of $45,827 for the six months ended June 30, 2025, included $76,332 for interest expense and a loss on the issuance of convertible debt of $85,867. These losses were offset by a $208,026 gain on the change in fair value of derivatives. #### Net Loss For the six months ended June 30, 2026, we had a net loss of $393,410 as compared to a net loss of $85,488 for the six months ended June 30, 2025. The $307,922 increase to our net loss is due to the reasons discussed above. ### Liquidity and Capital Resources #### Cash flow from operations Cash used in operating activities for the six months ended June 30, 2026, was $418,377. #### Cash Flows from Financing For the six months ended June 30, 2026, we received $35,000 in cash from the issuance of convertible notes payable. Together with $80,420 attributable to common stock issued during the period, net cash provided by financing activities was $115,420. ### Going Concern As of June 30, 2026, there is substantial doubt regarding our ability to continue as a going concern as we have not generated sufficient cash flow from revenue to fund our proposed business. We have suffered recurring losses from operations since our inception. In addition, we have yet to generate an internal cash flow from our business operations or successfully raised the financing required to develop our proposed business. As a result of these and other factors, our independent auditor has expressed substantial doubt about our ability to continue as a going concern. Our future success and viability, therefore, are dependent upon our ability to generate capital financing. The failure to generate sufficient revenues or raise additional capital may have a material and adverse effect upon us and our shareholders. On or about June 1, 2026, the Company began implementing certain operational and administrative changes in connection with its transition plan under new management. The Company has closed its former office located in Georgia and has relocated its principal office operations to Florida. In connection with the relocation, the Company has also established a new warehouse facility in Florida to support its ongoing business operations located at 1900 6th Ave, South Lake Worth, FL 33461. The Company is transitioning its business model away from the prior retail “cash and carry” walk-in traffic model in the rural town of Blackshear, Georgia, toward a business model focused more heavily based on Internet e-commerce and e-retail sales channels such as eBay and similar e-tailers launching nationwide and then moving on to International markets. ### Off Balance Sheet Arrangements We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. ### Critical Accounting Policies Refer to Note 2 to the Financial Statements for the six months ended June 30, 2026, for a discussion of our critical accounting policies and our Form 10-K for the year ended December 31, 2025, for a full discussion of our critical accounting policies and procedures. ## Market risk As filed, 154 characters. We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and, as such, are not required to provide the information under this Item. ## Controls and procedures As filed, 1,435 characters. #### Disclosure Controls and Procedures Our principal executive officer and principal financial officer have evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a - 15(e) and 15d - 15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this quarterly report. Based on their evaluation, each such person concluded that our disclosure controls and procedures were not effective as of March 31, 2026 due to a lack of segregation of duties. In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. #### Changes in Internal Control over Financial Reporting. Our management has evaluated whether any change in our internal control over financial reporting occurred during the last fiscal quarter. Based on that evaluation, management concluded that there has been no change in our internal control over financial reporting during the relevant period that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. ## Risk factors As filed, 154 characters. We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and, as such, are not required to provide the information under this Item. Filed Aug 14, 2026. Source: SEC EDGAR, the filing index for accession 0001683168-26-006414. Last ingested by Listed: Oct 24, 2026, 15:09 ET. No prices; not investment advice.